Author

J. Bravo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Kossenkov· 1 shared A. Register· 1 shared B. Kwong· 1 shared C. A. Dubin· 1 shared C. Gibson· 1 shared C. V. Weiss· 1 shared D. Anaya· 1 shared D. Fingerman· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Kossenkov

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune Diseases

D. Anaya, B. Kwong, S. Park, S. Biswas, J. Jeevan, M. Strobach, N. Khoshnoodi, A. Register, T. Klasson, S. Foos-Russ, J. Zeng, J. Banuelos, C. Gibson, J. Bravo, J. Flandez, , K. Walker

This paper introduces Ingenui-T, a method for rapid CAR T-cell manufacturing from whole blood, showing comparable or better functional activity than conventional methods.

bioRxiv · Jan 24, 2024 · PreprintImmunology

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas

V. W. Rebecca, M. Xiao, A. Kossenkov, T. Godok, G. S. Brown, D. Fingerman, G. M. Alicea, M. Wei, H. Ji, J. Bravo, Y. Chen, M. E. Fane, J. Villanueva, K. L. Nathanson, Q. Liu, , M. Herlyn

The paper identifies dasatinib as effective in restoring BRAFi/MEKi antitumor efficacy in 70% of resistant PDX models by targeting proteins involved in therapy escape.

bioRxiv · Jan 20, 2023 · PreprintCancer Biology

Molecular and evolutionary mechanisms of yeast thermotolerance

M. B. Abrams, C. A. Dubin, F. AlZaben, J. Bravo, P. M. Joubert, C. V. Weiss, R. B. Brem

The paper investigates the molecular and evolutionary mechanisms underlying thermotolerance in yeast, identifying positive selection at the ESP1 gene and its functional impact on growth at high temperatures.

bioRxiv · Aug 31, 2020Evolutionary Biology